DE3784693D1 - Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen. - Google Patents

Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.

Info

Publication number
DE3784693D1
DE3784693D1 DE8787311250T DE3784693T DE3784693D1 DE 3784693 D1 DE3784693 D1 DE 3784693D1 DE 8787311250 T DE8787311250 T DE 8787311250T DE 3784693 T DE3784693 T DE 3784693T DE 3784693 D1 DE3784693 D1 DE 3784693D1
Authority
DE
Germany
Prior art keywords
diseases
colonal
treating
producing
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787311250T
Other languages
English (en)
Other versions
DE3784693T2 (de
Inventor
David Anthony Richards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE3784693D1 publication Critical patent/DE3784693D1/de
Application granted granted Critical
Publication of DE3784693T2 publication Critical patent/DE3784693T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE8787311250T 1986-12-24 1987-12-21 Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen. Expired - Fee Related DE3784693T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868630913A GB8630913D0 (en) 1986-12-24 1986-12-24 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE3784693D1 true DE3784693D1 (de) 1993-04-15
DE3784693T2 DE3784693T2 (de) 1993-06-17

Family

ID=10609600

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787311250T Expired - Fee Related DE3784693T2 (de) 1986-12-24 1987-12-21 Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.

Country Status (13)

Country Link
US (1) US4985418A (de)
EP (1) EP0278174B1 (de)
JP (1) JPS63233998A (de)
KR (1) KR880007084A (de)
AT (1) ATE86491T1 (de)
AU (1) AU8296987A (de)
CA (1) CA1302262C (de)
DE (1) DE3784693T2 (de)
DK (1) DK678887A (de)
ES (1) ES2053571T3 (de)
GB (2) GB8630913D0 (de)
NZ (1) NZ223045A (de)
ZA (1) ZA879464B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
IT1256061B (it) * 1992-11-20 1995-11-23 Composizione terapeutica per uso rettale a base di flunisolide e/o deirelativi esteri per il trattamento di disordini intestinali a carattere infiammatorio
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
NL1006774C2 (nl) * 1996-08-14 1998-09-28 Univ Potchefstroom Anti-atherosclerose- en anti-trombotisch middel en het gebruik daarvan.
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5993782A (en) * 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
WO1999056698A2 (en) * 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
GB9823036D0 (en) * 1998-10-22 1998-12-16 Glaxo Group Ltd Fluticasone lotion having improved vasoconstrictor activity
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
US20050009848A1 (en) * 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) * 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090123390A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
JP2011503113A (ja) 2007-11-13 2011-01-27 メリテイジ ファーマ，インク． 胃腸炎の治療用組成物
US8865688B2 (en) 2008-10-03 2014-10-21 Dr. Falk Pharma Gmbh Compositions and methods for treatment of bowel diseases with granulated mesalamine
WO2010144865A2 (en) * 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335121A (en) * 1980-02-15 1982-06-15 Glaxo Group Limited Androstane carbothioates
CY1291A (en) * 1980-02-15 1985-10-18 Glaxo Group Ltd Androstane 17 beta carbothioates
US4578221A (en) * 1980-04-23 1986-03-25 Glaxo Group Limited Androstane carbothioic acids
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity

Also Published As

Publication number Publication date
DK678887A (da) 1988-06-25
GB2199747B (en) 1990-10-24
JPS63233998A (ja) 1988-09-29
US4985418A (en) 1991-01-15
CA1302262C (en) 1992-06-02
AU8296987A (en) 1988-06-30
ZA879464B (en) 1988-12-28
ES2053571T3 (es) 1994-08-01
DK678887D0 (da) 1987-12-22
GB8729756D0 (en) 1988-02-03
GB2199747A (en) 1988-07-20
EP0278174A3 (en) 1990-06-27
NZ223045A (en) 1989-11-28
KR880007084A (ko) 1988-08-26
GB8630913D0 (en) 1987-02-04
EP0278174A2 (de) 1988-08-17
ATE86491T1 (de) 1993-03-15
DE3784693T2 (de) 1993-06-17
EP0278174B1 (de) 1993-03-10

Similar Documents

Publication Publication Date Title
DE3784693D1 (de) Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE3772429D1 (de) Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
IT8019118A0 (it) Apparecchio manuale per la cura o il trattamento dei denti.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE3782028T2 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
PT83309A (de) Neue pyrrolo-benzimidazole pyrrolo-benzoxazole und pyrrolo-benzthiazole verfahren zu ihrer herstellung und diese verbindungen enthaltende arneimittel
ATE74605T1 (de) Tetracyclische chinazolinderivate, herstellung und verwendung.
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE3768150D1 (de) Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie.
DE69716341D1 (de) Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen
DE3686097T2 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE3784768D1 (de) Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.
ATE28878T1 (de) Neue 6alpha-methylprednisolon-derivate ihre herstellung und verwendung.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
DE68906028T2 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
DE68901234D1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee